Cargando…
Tumor Antigen-Dependent and Tumor Antigen-Independent Activation of Antitumor Activity in T Cells by a Bispecific Antibody-Modified Tumor Vaccine
New approaches of therapeutic cancer vaccination are needed to improve the antitumor activity of T cells from cancer patients. We studied over the last years the activation of human T cells for tumor attack. To this end, we combined the personalized therapeutic tumor vaccine ATV-NDV—which is obtaine...
Autores principales: | Fournier, Philippe, Schirrmacher, Volker |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049336/ https://www.ncbi.nlm.nih.gov/pubmed/21403859 http://dx.doi.org/10.1155/2010/423781 |
Ejemplares similares
-
Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy
por: Huang, Shuyu, et al.
Publicado: (2020) -
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
por: Hägerbrand, Karin, et al.
Publicado: (2022) -
Dual Function pH Responsive Bispecific Antibodies for Tumor Targeting and Antigen Depletion in Plasma
por: Bogen, Jan P., et al.
Publicado: (2019) -
Harnessing Oncolytic Virus-Mediated Anti-Tumor Immunity
por: Schirrmacher, Volker, et al.
Publicado: (2014) -
Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
por: Fournier, Philippe, et al.
Publicado: (2013)